. Author manuscript; available in PMC: 2017 Jul 27.

Published in final edited form as: Int J Tuberc Lung Dis. 2014 Sep;18(9):1026–1033. doi: 10.5588/ijtld.13.0749

Table 3.

Second-line DST results^* by patient category in Botswana’s fourth national anti-tuberculosis drug resistance survey, 2007–2008

	MDR-TB (n = 17) n (%)	DR-TB, not MDR-TB (n = 55) n (%)	Drug-susceptible TB (n = 85) n (%)
New patients
Any second-line drug resistance	11 (64.7)	4 (7.3)	8 (9.4)
Any FQ resistance^†	2 (11.8)	2 (3.6)	0
Any KM resistance	1 (5.9)	1 (1.8)	0
Any ETH resistance	11 (64.7)	5 (9.1)	8 (9.4)
XDR-TB^‡	0	NA	NA
Retreatment patients	(n = 7)	(n = 9)	(n = 11)
Any second-line drug resistance	2 (28.6)	2 (33.3)	1 (9.0)
Any FQ resistance^†	0	0	0
Any KM resistance	0	0	0
Any ETH resistance	2 (28.6)	2 (22.2)	1 (9.0)
XDR-TB^‡	0	NA	NA

Second-line DST was performed only on a subset of specimens sent to the National Reference Laboratory, South Africa, for additional testing, which included all those with resistance to isoniazid, rifampicin, ethambutol or streptomycin, and a 10% sample of those without resistance (susceptible); totals (n) listed in Table show the number per category with second-line DST results.

^†

Ofloxacin.

^‡

Defined as MDR-TB plus resistance to a FQ and resistance to any of the second-line injectable drugs (AMK, KM, capreomycin). Note: seven new patients underwent DST for AMK and no resistance to AMK was identified.

DST = drug susceptibility testing; MDR-TB = multidrug-resistant tuberculosis; DR-TB = drug-resistant TB; FQ = fluoroquinolones; KM = kanamycin; ETH = ethionamide; XDR-TB = extensively drug-resistant TB; NA = not available; AMK = amikacin.